- Report
- October 2024
- 181 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- April 2025
- 384 Pages
Global
From €5232EUR$5,600USD£4,426GBP
- Report
- February 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- March 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- May 2024
- 140 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1168EUR$1,250USD£988GBP
- Report
- March 2024
- 200 Pages
Global
From €3877EUR$4,150USD£3,280GBP
- Report
- March 2023
- 209 Pages
Global
From €3363EUR$3,600USD£2,845GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
Cidofovir is an antiviral drug used to treat infections caused by certain viruses, including cytomegalovirus (CMV) and adenovirus. It is used to treat CMV retinitis, a serious eye infection that can lead to blindness, and is also used to treat adenovirus infections in people with weakened immune systems. Cidofovir is administered intravenously and is usually given in combination with other antiviral medications. Common side effects include nausea, vomiting, and diarrhea.
Cidofovir is a part of the larger market of infectious diseases drugs, which are used to treat a variety of bacterial, viral, and fungal infections. These drugs are used to treat a wide range of conditions, from common colds to more serious illnesses such as HIV/AIDS and tuberculosis. Infectious diseases drugs are an important part of the healthcare system, as they help to reduce the spread of disease and improve patient outcomes.
Companies in the cidofovir market include Gilead Sciences, Merck, and Bristol-Myers Squibb. Show Less Read more